Abstract
Biomedical research results from the efforts of individuals as well as groups working in private laboratories, health care institutions, universities and research centres. In contemporary society, such research has become a more social or public enterprise, of interest not only to those who participate directly as researchers or research subjects, but to governments, commercial entities and the public at large. As with all human conduct, the process of developing hypotheses, designing research protocols and gathering, interpreting and reporting results has many moral aspects or “forks in the road” where the choices to be made may have implications for how one should, or should not act.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Advisory Committee on Human Radiation Experiments 1996. Final Report, New York: Oxford University Press.
American College of Physicians 1990. “Position Paper: Physicians and the Pharmaceutical Industry” Annals of Internal Medicine, Vol. 112(8), pp. 624–626.
Annas, G. 1991. “Ethics Committees: From Ethical Comfort to Ethical Cover” Hastings Centre Report, Vol. 21, p. 18.
Association of Academic Health Centres 1993. “New Opportunities Create New Problems” The Ethical Dimensions of the Biological Sciences, R.E. Bulger, E. Heitman & S.J. Reiser (Eds.), New York: Cambridge University Press, pp. 251–259.
Beecher, H.K. 1966. “Ethics and Clinical Research” New England Journal of Medicine, Vol. 475, pp. 1354–1360.
Bell, J., Whiton, J. & Connelly, S. 1998. Final Report: Evaluation of NIH Implementation of Section 491 of the Public Health Service Act, Mandating a Program of Protection for Research Subjects, prepared for the Office of Extramural Research, National Institutes of Health.
Bigorra, J. & Baños, J.E. 1990. “Weight of Financial Reward in the Decision by Medical Students and Experienced Healthy Volunteers to Participate in Clinical Trials” European Journal of Clinical Pharmacology, Vol.38, pp. 443–446.
Brody, B. 1996. “Conflicts of Interest and Validity of Clinical Trials” Conflicts of Interest in Clinical Practice and Research, R.G. Spece, D.S. Shimm & A.E. Buchanan (Eds.), New York: Oxford University Press, pp. 407–417.
Bulger, R.E., Heitman, E. & Reiser, S.J. 1993. “The Scientist and Industry: Conflicts of Interest and Conflicts of Commitment” The Ethical Dimensions of the Biological Sciences, R.E. Bulger, E. Heitman & S.J. Reiser (Eds), New York: Cambridge University Press, p. 221.
Canadian Medical Association 1994. “Physicians and the Pharmaceutical Industry” Canadian Medical Association Journal, Vol. 150(2), pp. 256A-C (Updated version available at http://www.cma.ca/inside/policybase/1998/05–09a.htm).
Davidson, R.A. 1986. “Source of Funding and Outcome of Clinical Trials” Journal of General Internal Medicine, Vol. 1, pp. 155–158.
Declaration of Indigenous Peoples of the Western Hemisphere Regarding the Human Genome Diversity Project 1995. Phoenix, Arizona February 19, 1995.
Emanuel, E.J. & Steiner, D. 1995. “Sounding Board: Institutional Conflict of Interest” New England Journal of Medicine, Vol. 332(4), pp. 262–267.
Endersbe, E., 1998 (Nov. 17). “Lure of Riches Fuels Testing”, Boston Globe.
Francis, L. 1996. “IRBs and Conflicts of Interest” Conflicts of Interest in Clinical Practice and Research, R.G. Spece, D.S. Shimm & A.E. Buchanan (Eds.), New York: Oxford University Press, pp. 418–437.
Freedman, B., Weijer, C. & Glass, K. 1996a. “Placebo Orthodoxy in Clinical Research I: Empirical and Method-ological Myths” Journal of Law, Medicine & Ethics, Vol. 24(3), pp. 243–251.
Freedman, B., Glass, K. & Weijer, C. 1996b. “Placebo Orthodoxy in Clinical Research II: Ethical, Legal, and Regulatory Myths” Journal of Law, Medicine & Ethics, Vol. 24(3), pp. 252–259.
Freestone, D.S. & Mitchell, H. 1993. “Inappropriate Publication of Trial Results and Potential for Allegations of Illegal Share Dealing” British Medical Journal, Vol. 306(6885), pp. 1112–1114.
Genewatch, 1990. “Proposed Conflict-of-Interest Guidelines Withdrawn” Vol. 6(2–3), p. 5.
Glass, B. 1993. “The Ethical Basis of Science” The Ethical Dimensions of the Biological Sciences, R.E. Bulger, E. Heitman & S.J. Reiser (Eds.), New York: Cambridge University Press, pp. 43–55.
Glass, B. 1965, “The Ethical Basis of Science” Science, Vol. 150, pp. 1254–1261.
Glass, K.C., Weijer, C., Palmour, R.M., Lemmens, T.M. & Shapiro, S.H. 1997. “Structuring the Review of Human Genetics Protocols Part II: Diagnostic and Screening Studies” IRB: A Review of Human Subjects Research, Vol. 19(3–4), pp. 1–13.
Horton, R. 1997. “Conflicts of Interest in Clinical Research: Opprobrium or Obsession” The Lancet, Vol. 349, pp. 1112–1113.
Horton, R. 1995. “The Rhetoric of Research” British Medical Journal, Vol. 310, pp. 985–88.
Huth, E.J. 1993. “Irresponsible Authorship and Wasteful Publication” The Ethical Dimensions of the Biologi-cal Sciences, R.E. Bulger, E. Heitman & S.J. Reiser (Eds.), New York: Cambridge University Press, pp. 134–137.
International Committee of Medical Journal Editors 1993. “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” JAMA, Vol. 269, pp. 2282–2286.
Katz, J. 1972. Experimentation with Human Beings, New York: Russell Sage Foundation.
Katz, J. 1996. “Informed Consent to Medical Entrepreneurialism” Conflicts of Interest in Clinical Practice and Research, R.G. Spece, D.S. Shimm & A.E. Buchanan (Eds.), New York: Oxford University Press, pp. 286–299.
Korenman, S. 1993. “Conflict of Interest and Commercialization of Research” Academic Medicine, Vol. 68(9, supp.3), pp. S18–S22.
The Lancet [Editorial]. 1997a. “Good Manners for the Pharmaceutical Industry” Vol. 349, p. 1635.
The Lancet [Editorial]. 1997b. “A Curious Stopping Rule from Hoechst Marion Roussel” Vol. 350, p. 155.
Lemmens, T. & Elliott C. (in press) “Guinea Pigs on the Payroll: the Ethics of Paying Research Subjects” Accountability in Research.
Lemmens, T. & Freedman, B. 1997. “Selling Ethics and Protecting Subjects? Conflict of Interest and Commercial Research Review” (submitted for publication).
Lemmens, T. & Singer, P. 1998. “Bioethics for Clinicians, 17: Conflict of Interest in Research, Education and Patient Care” Canadian Medical Association Journal, Vol. 159(8), pp. 960–965.
Levine, R. 1986. Ethics and Regulation of Clinical Research (2nd ed.), Baltimore: Urban and Schwarzenberg.
Lexchin, J. 1993. “Interactions Between Physicians and the Pharmaceutical Industry: What Does the Literature Say?” Canadian Medical Association Journal, Vol. 149(10), pp. 1401–1407.
Lind, S.E. 1990. “Finder’s Fees for Research Subjects” New England Journal of Medicine, Vol. 323, pp. 192–195.
Maatz, C.T. 1992. “University Physician-Researcher Conflicts of Interest: the Inadequacy of Current Controls and Proposed Reform” High Technology Law Journal, Vol. 7(1), pp. 138–188.
Marshall, E. 1999. “NIMH to Screen Studies for Science and Human Risks” Science, Vol. 283(5401), pp. 464–465.
Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada and Social Sciences and Humanities Research Council of Canada 1998. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Ottawa: Minister of Supply and Services.
Moore v Regents of the University of California 793 P.2d 479, 481 (Cal. 1990).
National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC.
National Bioethics Advisory Commission 1998. Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Volume I: Report and Recommendations of the National Advisory Commission. Maryland: National Bioethics Advisory Commission.
Office of Inspector General 1998a. Institutional Review Boards: Their Role in Reviewing Approved Research, Department of Health and Human Services.
Office of Inspector General 1998b. Institutional Review Boards: Promising Approaches, Department of Health and Human Services.
Office of Inspector General 1998c. Institutional Review Boards: The Emergence of Independent Boards, Department of Health and Human Services.
Office of Inspector General 1998d. Institutional Review Boards: A Time for Reform, Department of Health and Human Services.
Perry, C.B. 1994. “Conflicts of Interest and the Physician’s Duty to Inform” American Journal of Medicine, Vol. 96, pp. 375–380.
Petersdorf, R.G. 1993. “The Pathogenesis of Fraud in Science” The Ethical Dimensions of the Biological Sci-ences, R.E. Bulger, E. Heitman & S.J. Reiser (Eds.), New York: Cambridge University Press, pp. 95–98.
Phillips, R.A. & Hoey, J. 1998. “Constraints of Interest: Lessons at the Hospital for Sick Children” Canadian Medical Association Journal, Vol. 159(8), pp. 955–957.
Pincus, H.A., Lieberman, JA. & Ferris, S. (Eds.) 1999. Ethics in Psychiatric Research, A Resource Manual for Human Subjects Protection, American Psychiatric Association: Washington.
Reibl e Hughes 1980. 114 D.L.R. (3d) 1 (Supreme Court of Canada).
Rothman, K.J. 1993. “Conflict of Interest: The New McCarthyism in Science.” JAMA, Vol. 269, pp. 2782–2784.
Smith, R. 1996. “Time to Face Up to Research Misconduct” British Medical Journal, Vol. 312(7034), pp. 789–790.
Spece, R.G., Shimm, D.S. & Buchanan, A.E. (Eds.) 1996. Conflicts of Interest in Clinical Practice and Research, New York: Oxford University Press.
Stelfox, H.T., Chua, G., O’Rourke, K. & Detsky, A.S. 1998. “Conflict of Interest in the Debate Over Calcium-Channel Antagonists” New England Journal of Medicine, Vol. 338(2), pp. 101–106.
Thompson, D. 1993. “Understanding Financial Conflicts of Interest” New England Journal of Medicine, Vol. 329(8), pp. 573–576.
U.S. Department of Health, Education and Welfare 1973. Final Report of the Tuskegee Syphilis Study Ad Hoc Panel, Washington, D.C.: Government Printing Office.
U.S. General Accounting Office 1996. Scientific Research: Continued Vigilance Critical to Protecting Human Subjects, GAO/HEHS-96–72.
van Gelderen, C.E.M., Savelkoul, T.J.F., van Dokkum, W & Meulenbelt, J. 1993. “Motives and Perception of Healthy Volunteers Who Participate in Experiments” European Journal of Clinical Pharmacology, Vol. 45, pp. 15–21.
World Medical Association 1995 [1964, rev. 1975, 1983, 19891 “Declaration of Helsinki” W.T. Reich (Ed.), Encyclopedia of Bioethics (rev. ed.), New York: Simon and Schuster/Macmillan, pp. 2765–2767.
Woolf, P.K. 1993. “Pressure to Publish and Fraud in Science” The Ethical Dimensions of the Biological Sciences, R.E. Bulger, E. Heitman & S.J. Reiser (Eds.), New York: Cambridge University Press, pp. 100–103.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Glass, K.C., Lemmens, T. (1999). Conflict of Interest and Commercialization of Biomedical Research. In: Caulfield, T.A., Williams-Jones, B. (eds) The Commercialization of Genetic Research. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4713-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4713-6_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7135-9
Online ISBN: 978-1-4615-4713-6
eBook Packages: Springer Book Archive